Amy Schulman - Jun 25, 2024 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Role
Director
Signature
By: Brett Budzinski, Attorney-in-Fact For: Amy Schulman
Stock symbol
ALNY
Transactions as of
Jun 25, 2024
Transactions value $
-$924,715
Form type
4
Date filed
6/27/2024, 04:04 PM
Previous filing
May 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Options Exercise $1.12M +8.5K +100.76% $131.21 16.9K Jun 25, 2024 Direct F1
transaction ALNY Common Stock Sale -$2.04M -8.5K -50.19% $240.00 8.44K Jun 25, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALNY Stock Option (right to buy) Options Exercise $0 -8.5K -75.56% $0.00 2.75K Jun 25, 2024 Common Stock 8.5K $131.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024.
F2 This stock option was fully vested and exercisable as of June 1, 2016.